Vanguard Capital Management’s CytomX Therapeutics CTMX Stock Holding History
Bought
Maintained
Sold
Other funds holding CTMX
KCM
Vanguard Capital Management's CTMX Position: Q3 2026 in Review
Vanguard Capital Management increased its CytomX Therapeutics (CTMX) stake by 2.4% in Q3 2026, buying an estimated $690K and bringing the position to 8,732,337 shares worth $23.8M. The position accounts for ﹤0.01% of the portfolio, ranked #2305.
Vanguard Capital Management first reported a position in CTMX in Q1 2026 and has held it in 3 quarters since. The position peaked at $41M in Q1 2026. 193 funds tracked by Wall St. Rank hold CTMX as of Q3 2026.
- Vanguard Capital Management held 8,732,337 shares of CytomX Therapeutics worth $23.8M as of Q3 2026.
- Vanguard Capital Management bought 206,880 CytomX Therapeutics shares in Q3 2026, an estimated $690K.
- CytomX Therapeutics made up ﹤0.01% of Vanguard Capital Management's portfolio in Q3 2026, its #2305 holding.
- Vanguard Capital Management first reported a position in CytomX Therapeutics in Q1 2026 and has held it in 3 quarters since.
- Vanguard Capital Management's CytomX Therapeutics position peaked at $41M in Q1 2026.
- 193 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q3 2026.
Based on Vanguard Capital Management's 13F filing for Q3 2026, filed 13 Nov 2026.